Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) – Research analysts at Leerink Swann upped their FY2019 earnings per share (EPS) estimates for shares of Sucampo Pharmaceuticals in a research note issued on Monday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will earn $1.79 per share for the year, up from their prior forecast of $1.65. Leerink Swann currently has a “Market Perform” rating and a $15.00 target price on the stock. Leerink Swann also issued estimates for Sucampo Pharmaceuticals’ FY2020 earnings at $2.02 EPS and FY2021 earnings at $2.19 EPS.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period last year, the company earned $0.30 EPS.
Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) traded down $0.10 during mid-day trading on Wednesday, hitting $18.05. The stock had a trading volume of 6,048,610 shares, compared to its average volume of 4,786,275. The company has a market cap of $841.80, a price-to-earnings ratio of -5.39, a P/E/G ratio of 5.04 and a beta of 1.45. Sucampo Pharmaceuticals has a 12-month low of $9.30 and a 12-month high of $18.20. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37.
In other news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total value of $825,000.00. Following the completion of the transaction, the insider now owns 52,023 shares in the company, valued at approximately $858,379.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.13% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SCMP. Point72 Asset Management L.P. purchased a new position in shares of Sucampo Pharmaceuticals in the 3rd quarter valued at approximately $21,989,000. Prudential Financial Inc. lifted its stake in shares of Sucampo Pharmaceuticals by 871.6% in the 3rd quarter. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company’s stock valued at $4,842,000 after purchasing an additional 368,090 shares during the period. Vanguard Group Inc. raised its stake in Sucampo Pharmaceuticals by 13.0% during the second quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock valued at $17,287,000 after buying an additional 189,561 shares during the last quarter. Systematic Financial Management LP purchased a new position in Sucampo Pharmaceuticals during the second quarter valued at $1,648,000. Finally, Royce & Associates LP raised its stake in Sucampo Pharmaceuticals by 9.7% during the third quarter. Royce & Associates LP now owns 1,171,731 shares of the biopharmaceutical company’s stock valued at $13,826,000 after buying an additional 103,808 shares during the last quarter. Institutional investors own 65.29% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3127623/fy2019-earnings-estimate-for-sucampo-pharmaceuticals-inc-issued-by-leerink-swann-scmp.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.